)
Visual
earnings real time
Sangamo Therapeutics
Sangamo Therapeutics (SGMO) investor relations material
Sangamo Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Advanced clinical and preclinical pipeline in Fabry disease, chronic neuropathic pain, and prion disease, with first neurology clinical study patient recruitment and enrollment.
Fabry disease program (ST-920) achieved positive registrational data, with durable kidney and cardiac outcomes, and is on a clear path to potential accelerated approval.
Productive regulatory interactions with FDA and MHRA for Fabry and prion disease programs, with FDA reaffirming eGFR slope as endpoint.
Neurology pipeline includes ST-503 (chronic neuropathic pain, Phase 1/2 trial initiated) and ST-506 (prion disease, CTA submission expected mid-2026).
Ongoing business development efforts to secure Fabry commercialization partner and advance industry partnerships.
Financial highlights
Q3 2025 net loss of $34.9 million, or $0.11 per share; nine-month net loss of $85.5 million.
Revenues for Q3 2025 were $0.6 million, down sharply from $49.4 million in Q3 2024, mainly due to prior year Genentech collaboration revenue.
Cash and cash equivalents as of September 30, 2025: $29.6 million, with $6 million from Pfizer and $9.1 million from at-the-market offering received after quarter-end.
Non-GAAP operating expenses for Q3 2025 were $33.0 million; GAAP OpEx was $36.1 million.
Up to $5.9 billion in potential future milestones and exercise fees from partnerships.
Outlook and guidance
Cash runway expected to fund operations into Q1 2026, including recent Pfizer license fee and stock sale proceeds, but additional capital is required.
Preparing for a BLA submission for Fabry disease gene therapy as early as Q1 2026, contingent on funding and regulatory agreement.
Prion disease CTA submission expected as early as mid-2026; preliminary clinical data for neurology programs anticipated from early 2027.
2025 GAAP operating expenses expected to be $135–$155 million; non-GAAP OpEx expected at $125–$145 million.
Actively seeking new capital through equity, debt, and strategic collaborations.
Fabry BD: What's the next key milestone?
ST-503: What efficacy signal defines success?
STAC-BBB: How does success unlock neurology?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- ACE
Higher margins and PAT in Q3 FY26 despite flat revenue and lower sales volumes. - GODREJAGRO
Q3 FY26 revenue reached ₹2,718.32 crore with 33.9% adjusted PAT growth and strong segment gains. - QBY
Profitability returns in 2025, driven by sector focus, AI, and international expansion. - NAZARA
EBITDA and margins rose on IP focus, but regulatory changes led to major impairment losses. - HAPPYFORGE
Stable to growing financials, strong margins, and disciplined IPO fund use with no audit concerns. - RBA
Q3 revenue rose 16.5% in India; Inspira Global to acquire a controlling stake and infuse capital. - 6674
Profits and dividends revised upward on strong battery sales and improved margins. - BOROUGE
$1.1B net profit, 37% EBITDA margin, record sales, and major restructuring drive future growth. - 8059
Record Q3 profits and strong segment growth support an upwardly revised full-year outlook. - 7011
Strong order intake and profit growth drive upward revision of FY2025 forecasts and reflect key divestiture impact.
Next Sangamo Therapeutics earnings date
Q4 202519 Mar, 2026
Sangamo Therapeutics
Next Sangamo Therapeutics earnings date
Q4 202519 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in therapeutic genome editing. The company's lead program is focused on treating inherited blood disorder beta-thalassemia and sickle cell disease by ex vivo genome editing in hematopoietic stem and progenitor cells from adult patients. It is also focusing on genome editing for HIV/AIDS; hemophilia; Huntington's disease; LCA6; other rare and infectious diseases; cancer and degenerative conditions. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage